Organ Transplantation

Risk of type 2 diabetes rises after COVID; organ transplant from donors who had COVID likely safe

Coronavirus Disease (COVID-19) Pandemic, COVID-19 Severe Complications, COVID-19 Studies, JAMA Psychiatry, Medical Journals, Neuropsychiatric Diseases, Organ Transplantation, R&D, Reuters, The Lancet Diabetes & Endocrinology, Type 2 Diabetes, U.S. Department of Veterans Affairs

People may be at increased risk for developing diabetes for up to a year after a diagnosis of COVID-19, according to two studies. Additionally, organ donation from dying donors with current or previous COVID-19 infection is likely safe, transplant teams from the United States and Italy will report at the April 2022 European Congress of Clinical Microbiology & Infectious Diseases meeting.

FDA Advisory Committee Recommends Use Maribavir to Treat Post-Transplant Recipients with CMV Infection and Disease Refractory to Treatment With or Without Resistance

Adults, Advisory Panels, Antimicrobial Drugs Advisory Committee, Clinical Trials, Cytomegalovirus Infections, Organ Transplantation, R&D, Recommended For Approval, Takeda

The U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of Takeda Pharmaceutical Company Limited’s maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease withgenotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Janssen, Theravance Ink $1 Billion Collaboration

Business, Clinical Trials, Collaborations, Crohn's Disease, Gastrointestinal Diseases, Inflammatory Bowel Disease, Janus Kinase (JAK) Inhibitors, Organ Transplantation, Ulcerative Colitis

Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).